Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- ROCKII ROCK-II 2 1 Rho-A MYPT-1 MLC-2 Th-17 p-164 KIAA-0619
- Product Overview:
Rho-associated protein kinase 2 (ROCK2) is a serine/threonine kinase that has roles in cytoskeletal organization and autoimmunity, as well as cell survival, proliferation, and apoptosis.{60550,60551,61836} It exists as a homodimer where each monomer is composed of an N-terminal kinase domain, a coiled-coil region that contains the Rho-binding domain, and a C-terminal pleckstrin homology (PH) domain that contains a cysteine-rich C1 domain and acts as an autoinhibitory region.{60552,60551} Rock2 mRNA is expressed in brain, muscle, heart, lung, and placenta, localized to the cytosol and nucleus, associated with the centrosome, and co-localized with actin and vimentin in a cell-type-specific manner.{60550,60551} Binding of ROCK2 to GTP-bound RhoA induces activation of ROCK1, which phosphorylates a variety of downstream targets, including myosin light chain (MLC) phosphatase 1 (MYPT1) and MLC2, that have diverse roles in cytoskeletal organization.{60551} Additionally, ROCK2 is cleaved and activated by proteases, including granzyme B and caspase-2, to induce apoptosis.{60550} Pharmacological inhibition of ROCK2 restores immune homeostasis and shifts the helper T (Th17)/regulatory T (Treg) cell balance towards Tregs in various animal models of autoimmunity and chronic graft versus host disease (GVHD).{61836} Rock2 knockdown decreases the fibrogenic response in a mouse model of diabetic kidney disease.{61837} Cayman’s ROCK2 (human, recombinant) protein can be used for enzyme activity assays.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.